支持临床试验多样性:医学公平突破中心成熟度模型
医学公平突破(EQBMED)倡议开发了一个整体、协作、由中心驱动的形成性成熟度模型及配套评估,用于记录中心开展行业申办临床试验和丰富试验多样性的现有能力并识别成长机会。该模型整合了研究运营与社区参与两个传统上分离的组成部分。文章介绍了模型开发方法,并报告了在美国三个中心早期实地测试的结果。
要点
- EQBMED成熟度模型整合研究运营与社区参与,以评估中心临床试验多样性能力。
- 早期三个美国中心床位规模小于250至1K张不等,临床试验能力与社区参与水平各异。
- 成熟度评估帮助中心识别并优先推进关键领域,各中心均取得实质性进展。
核心结论
- 对临床试验多样性的战略投资需要以结构化的中心成熟度评估作为协作行动的起点。
- 作者提出EQBMED成熟度模型,作为朝着增加临床研究中多样化人群代表性方向迈出的第一步。
研究设计与样本
- EQBMED倡议开发了一个整体、协作、由中心驱动的形成性模型及配套评估,用于记录中心当前能力并识别成长机会。
- 该模型建立在既往工作基础上,整合了研究运营与社区参与两个历史上不同的组成部分。
- 在美国三个中心进行了早期实地测试,同时收集了关于内容效度(如清晰度、全面性、术语)和可行性(如收集所需信息与数据的能力、所需时间)的反馈。
主要发现
- 首批三个中心规模各异(如<250至1K张床位),临床试验能力和社区参与水平不同。
- 成熟度评估为中心识别并优先推进提升临床试验多样性能力的关键领域奠定了基础,每个中心均取得了实质性进展。
- 描述了为改进评估和简化流程所做的修订。
- EQBMED项目将在各类中心类型(如联邦合格健康中心、安全网医院)部署该评估,并根据需要进一步修订。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- EQBMED项目将在各类中心类型(如联邦合格健康中心、安全网医院)部署该评估,并根据需要进一步修订。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among the most powerful barriers to broader inclusion of diverse participants in clinical trials are social determinants of health, trustworthiness of health care providers and research institutions, and competing pressures on potential participants. Nevertheless, current tools to assess organizational capabilities for clinical trial diversity focus primarily on trial infrastructure, rely solely on quantitative self-reported data, and lack meaningful assessment of capabilities related to community engagement. METHODS: The Equitable Breakthroughs in Medicine (EQBMED) initiative developed a holistic, collaborative, site-driven formative model and accompanying assessment to catalog sites' current capabilities and identify opportunities for growth in both conducting industry-sponsored clinical trials and enriching diversity of those trials. The model builds upon prior work and reflects unification of two historically distinct components-research operations and community engagement-since sustainable clinical trial diversity efforts must overcome these silos. Here we present the methodology we used to develop the model and accompanying assessment, describe how findings can support clinical trial diversity efforts, and report findings from early field testing at three U.S. sites. RESULTS: The first three sites were diverse in size (e.g., < 250-1 K beds), with varying levels of clinical trial capabilities and community engagement. The maturity assessment laid the foundation for sites to identify and prioritize key areas to advance clinical trial diversity capabilities, and each has made tangible progress. In parallel to completing the assessment with these early sites to understand their maturity and set actionable goals, we also collected their feedback on content validity (e.g., clarity, comprehensiveness, terminology) and feasibility (e.g., ability to collect needed information and data, time required). We describe refinements made to improve the assessment and streamline the process. The EQBMED program will deploy the assessment across various site types (e.g., FQHCs, safety net hospitals) and make further refinements as warranted. CONCLUSIONS: Strategic investment in clinical trial diversity requires structured assessment of site maturity as a starting point for collaborative action. We propose the EQBMED maturity model as a first step toward informing efforts to increase representation of diverse populations in clinical research.
引用
- Harris T, Nunez-Smith M, Suttiratana SC, et al. Supporting diversity in clinical trials: the equitable breakthroughs in medicine site maturity model. Trials. 2024. PMID: 39543751. doi:10.1186/s13063-024-08594-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。